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AbstrAct
Background Mobile health applications (apps) are available 
to enable people with rheumatic and musculoskeletal diseases 
(rMDs) to better self-manage their health. However, guidance 
on the development and evaluation of such apps is lacking.
Objectives the objective of this eUlar task force was 
to establish points to consider (Ptc) for the development, 
evaluation and implementation of apps for self-management 
of rMDs.
Methods a systematic literature review of app content and 
development strategies was conducted, followed by patient 
focus group and an online survey. Based on this information 
and along with task force expert opinion, Ptc were formulated 
in a face-to-face meeting by a multidisciplinary task force 
panel of experts, including two patient research partners. the 
level of agreement among the panel in regard to each Ptc was 
established by anonymous online voting.
Results three overarching principles and 10 Ptc were 
formulated. three Ptc are related to patient safety, considered 
as a critical issue by the panel. three are related to relevance 
of the content and functionalities. the requirement for 
transparency around app development and funding sources, 
along with involvement of relevant health professionals, were 
also raised. ease of app access across ages and abilities was 
highlighted, in addition to considering the cost benefit of apps 
from the outset. the level of agreement was from 8.8 to 9.9 
out of 10.
Conclusion these eUlar Ptc provide guidance on important 
aspects that should be considered for the development, 
evaluation and implementation of existing and new apps.
InTROduCTIOn
Mobile health (mHealth) technologies have 
the capacity to transform the mode and 
quality of healthcare, allowing people to take 
a more proactive role in their health and well-
being.1 This is increasingly achieved using 
smart phone technology (sometimes linked 
to wearable sensors) that gathers health-re-
lated data via medical application interfaces.2 
By enabling people to access and share their 
health information, mHealth has the capacity 
to empower individuals to take a more active 
role in self-managing their health and well-
being.3 The number of available mobile 
health applications (apps) has exponentially 
grown over the past few years and so has the 
number of users.4 Apps are designed for a 
wide range of users, from healthy individuals 
to people living with long-term conditions 
Key messages
What is already known about this subject?
 ► there is unmet need to standardise the development 
of mHealth apps for self-management in rheumatic 
and musculoskeletal diseases.
What does this study add?
 ► this work aimed at developing guidance in for the 
development, evaluation and implementation of 
self-management apps in rheumatology.
How might this impact on clinical practice?
 ► these points to consider will serve as a basis for the 
evaluation and endorsement of existing apps or the 
development of future apps aiding self-management 
by people living with rheumatic and musculoskeletal 
diseases.
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including, but not limited to, rheumatic and muscu-
loskeletal diseases (RMDs),5 psychiatric,6 respiratory,7 
cardiovascular diseases8 and diabetes mellitus.9
The use of such apps is becoming more and more popular 
among people living with long-term conditions. Aside 
from the increasing popularity of apps among people with 
long-term conditions, mHealth apps can support disease 
assessment by health professionals and enhance doctor–
patient interactions. For example, they have been useful 
tools to facilitate the calculation of disease activity scores, 
and monitor patients through the collection of clinical 
and laboratory parameters.10 A survey performed among 
people living with RMDs (429 respondents) revealed that 
around 50% were aware of the existence of such apps.11 
This corresponds with previous works performed in 
different specialties. For example, a previous survey among 
people living with type 1 diabetes mellitus found that 40% 
of respondents reported being aware of self-management 
apps.12 Alongside the value of apps in patient self-empower-
ment, they can also facilitate patient communication with 
health professionals,13 improve treatment adherence,14 
provide condition-specific education and enable remote 
condition monitoring.15 16
Recent studies assessing the quality of rheumatoid 
arthritis apps showed that most apps were not achieving 
high-quality scores and that data on funding and origin 
were frequently unavailable.17 18 These studies raise 
concerns and highlight the need for benchmarking the 
quality of mHealth apps to ensure patient safety, among 
other aspects. Scientific bodies, such as the EULAR, 
should contribute to quality control measures of existing 
apps, fulfilling this unmet need. Therefore, the aim of 
this project was to develop EULAR points to consider 
(PtC) for the development, evaluation and implementa-
tion of apps aiding self-management of RMDs.
MeTHOds
The task force (TF) was led by two convenors (AN and 
FB) and two methodologists (EN and LG) and the fellow 
(AN) according to the 2014 updated EULAR Standardised 
Operating Procedures.19 This was modified with a single 
face-to-face meeting to take place, with part of the budget 
dedicated to focus group realisation. The TF consisted of 
19 members from 10 countries across Europe. The panel 
included 15 rheumatologists, 2 patient research partners 
and 2 health professionals (occupational therapists). The 
TF also included two representatives from the EMerging 
EUlar NETwork.
Preparatory TF work: systematic literature review and mixed-
methods study
A systematic literature review (SLR) was conducted by 
the fellow (AN) under the supervision of the methodolo-
gists.20 The SLR objective was to obtain detailed informa-
tion on existing mHealth apps to aid self-management 
among people living with RMDs, focusing on content 
and development methods. Due to the peculiarities of 
the topic, and the importance of patient input in this 
domain, a second part of this work focused on a mixed-
methods study (including a qualitative and a quantitative 
approach) to obtain an in-depth understanding of the 
topic through direct patient feedback. We first conducted 
a patient focus group in the UK, the findings of which 
informed the design of an international patient survey. 
This survey provided wider insights into the needs, views, 
experiences and preferences in mHealth apps to aid 
self-management among people living with RMDs.11 This 
preparatory material was used as a basis for the formula-
tion of the draft recommendation list by the TF steering 
group (fellow, convenor, comethodologists).
Face-to-face meeting
The results of the SLR and mixed-methods study were 
sent to the TF before the face-to-face meeting and were 
subsequently presented to the TF during the face-to-face 
meeting in November 2018. This formed the basis of 
in-depth discussions by the TF. The presented evidence 
was followed by the presentation of preliminary draft 
recommendations to the TF one by one, along with the 
corresponding evidence. During the meeting, the draft 
recommendations were reformulated, and some themes 
were merged. Discussions culminated in the formulation 
of a definition for mHealth apps, overarching principles 
and PtC. Consensus on the final wording of overarching 
principles and PtC was considered final if >75% of the 
TF members voted in favour of the PtC at the first round, 
>67% at the second >50% at the third round.
level of agreement
The Oxford Levels of Evidence from Ia (Evidence from 
meta-analysis of randomised controlled trials) to IV 
(Evidence from expert committee reports or opinions 
or clinical experience of respected authorities, or both) 
were applied for each PtC.21 Subsequent strength of 
statement was assigned ranging from A (directly based 
on level I evidence) to D (directly based on level IV 
evidence or extrapolated recommendations from level I, 
II or III evidence). The percentage of agreement during 
the meeting was recorded for the overarching principles, 
through a vote by hand raise.
Subsequently, members of the TF were asked, by email, 
to provide their level of agreement for each PtC, through 
anonymous voting on an 11-point Likert scale from 0 to 
10 (0: completely disagree, 10: completely agree). The 
mean and SD of the level of agreement with each state-
ment were calculated.
ResulTs
Target population
These PtC are intended to assist in evaluating the quality 
of existing apps, while guiding the development, evalua-
tion and implementation of future apps aiding self-man-
agement among people living with RMDs.
The target audience are apps users, including patients, 
parents/carers, health professionals, rheumatologists, 
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Table 1 Three overarching principles and 10 points to consider (PTC) for the development, evaluation and implementation of 
apps to aid self-management among people living with rheumatic and musculoskeletal diseases (RMDs)
Overarching principles Agreement (%)
Apps* for self-management support the health, well-being and 
empowerment of people living with RMDs.
100
Apps* require an overarching conceptual framework, which defines the 
target population and purpose of the app.
100
User privacy and safety are fundamental considerations for all apps* 
aimed at people living with RMDs.
100
PtC Oxford level of 
evidence
Strength of 
statement
Level of agreement
Mean (SD)
  1. The information content in self-management apps should be up 
to date, scientifically justifiable, user acceptable and evidence based 
where applicable.
Level 5 D 9.8 (0.4)
  2. Apps should be relevant and tailored to the individual needs of 
people with RMDs.
Level 5 D 9.7 (0.5)
  3. The design, development and validation of self-management apps 
should involve people with RMDs and relevant healthcare providers.
Level 5 D 9.8 (0.6)
  4. There should be transparency on an app’s developer, funding 
source, content validation process, version updates and data 
ownership.
Level 5 D 9.9 (0.3)
  5. Data collection as part of apps must adhere to all applicable 
regulatory frameworks, particularly data protection.
Level 5 D 9.9 (0.3)
  6. Apps must not result in physical or emotional harm to people with 
RMDs.
Level 5 D 9.3 (1)
  7. Apps could facilitate patient–healthcare provider communication 
and contribute to electronic health records or research.
Level 5 D 9.4 (0.9)
  8. App design should consider accessibility of people with RMDs 
across ages and abilities.
Level 5 D 9.4 (0.9)
  9. If a social network is an important component of an app, structures 
should be in place to ensure appropriate content moderation.
Level 5 D 9.5 (0.6)
  10. The rheumatology community should consider the cost-benefit 
balance of apps before endorsement and/or promotion.
Level 5 D 8.9 (1.3)
*An app is a small programme that can be downloaded and installed on a mobile device. For the purpose of these PtC, the definition takes a 
focus on self-management of RMDs.
PtC, points to consider.
patient organisations, scientific societies, app developers 
and regulatory agencies.
Overarching principles
A definition of apps and three overarching principles 
were formulated (table 1). The overarching principles 
were formulated based on the aspects felt as the most 
important by the TF.
Apps for self-management have the clear mission of 
supporting health, well-being and empowerment of people 
living with RMDs.2 22 Those developing apps should follow 
a step-by-step framework in line with their aim and target 
population.23 24 This framework should be defined before-
hand and should guide the development and evaluation 
phases, by involving relevant stakeholders and collecting 
relevant data in the pilot phase. This process should then 
be implemented in a validation phase25 in a collaborative 
approach with all relevant stakeholders.26
More importantly, it was felt as fundamental by the TF 
to emphasise the need of ensuring patient safety and data 
security.27 28 Patient safety is described as making no phys-
ical or emotional harm to patients.29 Data security refers 
to protection of data against unauthorised use. Those 
two concepts form the basis of regulations in the Euro-
pean Union (EU) and USA.30
Agreement was 100% by vote during the meeting for 
the three overarching principles.
Points to consider
Ten PtC were formulated. The level of evidence as well 
as strength of statement and level of agreement are 
provided for each overarching principles and PtC in 
table 1. The overall level of evidence ranged from 4 to 5, 
with a subsequent strength of statement from C to D. The 
level of agreement was high, with full agreement among 
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the TF for overarching principles, and a mean ranging 
from 8.9 to 9.9 for each of the 10 PtC.
For these PtC, an app was defined as follows: an app is 
a small programme that can be downloaded and installed 
on a mobile device. For the purpose of these PtC, the 
definition takes a focus on self-management of RMDs.
Ptc 1: the information content in self-management apps should be 
up to date, scientifically justifiable, user acceptable and evidence 
based where applicable
A ‘user’ is defined as a person living with RMDs and/or 
their families/carers. The TF emphasises that any medical 
information provided to people living with RMDs should 
be scientifically accurate and evidence based; however, 
this should be balanced to ensure that information can be 
understood and interpreted by people living with RMDs. 
Any medical content provided by self-management apps 
should be validated by appropriate experts.31 32 A previous 
review of existing rheumatology apps highlighted that 
the source of medical information was lacking in 40% of 
the screened apps.18 The TF emphasised the importance 
of citing sources whenever possible.
Ptc 2: apps should be relevant and tailored to the individual needs 
of people with rMDs
Apps need to be tailored to the needs of people living 
with RMDs, in addition to encompassing different aspects 
of their conditions in a relevant manner. This principle 
should be applicable for both condition-specific and 
non-specific apps. The scope of apps should be clearly 
defined, and features included in apps should be relevant 
to the target audience. Patient priorities, for example, 
pain, function and fatigue, should be taken into account 
when designing apps.33 34
Ptc 3: the design, development and validation of self-management 
apps should involve people with rMDs and relevant healthcare 
providers
The SLR informing this work highlighted that health 
professionals and patients were rarely involved in every 
stage of app development. Patients were usually involved 
in the test phase, but less frequently in the design phase. 
Moreover, when in place, the design phase rarely included 
a qualitative phase. Since patients are the target users, app 
development should be patient centred and driven directly 
by the needs and priorities of people living with RMDs. 
Moreover, as medical content is provided and medical data 
are usually collected in such apps, healthcare providers, in 
particular rheumatologists, should be involved in the devel-
opment phase.31 32 Healthcare providers are defined as any 
physicians or other health professionals (eg, nurses, physio-
therapists and occupational therapists) involved in the care 
of people living with RMDs.35
Ptc 4: there should be transparency on an app’s developer, 
funding source, content validation process, version updates and 
data ownership
Important information such as the developer, funding 
source(s), advertisement and promotion, conflict of 
interest or date of last update were missing from the 
description of a significant number of apps.18 The TF 
considered that such information should be made 
publicly available for any app.
Ptc 5: data collection as part of an app must adhere to all 
applicable regulatory frameworks, particularly data protection
Applicable regulations and ethical principles should be 
followed if medical-related data are collected as part of 
apps, to ensure that appropriate data protection regula-
tions are adhered to, while promoting patient safety.30 The 
latter refers to physical or emotional harm, and includes 
data protection. Electronic data protection is extremely 
topical, with the recent implementation of regulations 
on a European level with the EU’s General Data Protec-
tion Regulation, as well as the existing 1996 US Health 
Insurance Portability and Accountability Act.36 37 More-
over, generic regulation and/or guidance pertaining to 
mobile apps have been developed on a national level in 
some EULAR countries, such as the 38UK and Spain.39
Ptc 6: apps must not result in physical or emotional harm to 
people with rMDs
According to WHO, patient safety is the absence of 
preventable harm to a patient during the process of 
healthcare and reduction of risk of unnecessary harm 
associated with healthcare to an acceptable minimum.40 
This concept was strongly perceived as crucial by all TF 
members and was therefore included in the overarching 
principles in addition to PtC 6. The content and function-
alities of apps should consider the well-being of people 
living with RMDs as a priority. Content that could poten-
tially cause emotional distress or suicidal ideation must 
be avoided. Appropriate signposting to relevant support 
organisations for people should also be provided when 
presenting potentially sensitive information which could 
elicit emotional and/or suicidal thoughts.
Ptc 7: apps could facilitate patient–healthcare provider 
communication and contribute to electronic health records or 
research
The sustainability of apps depends on their perceived 
need and continued use by people living with RMDs, as 
well as on the interaction around results connected with 
the physician or other healthcare providers. The lack of 
feedback on data collected by apps seems to affect app 
use and its cessation in diabetes.41 In addition to demon-
strating the capacity of apps to enhance patient–health-
care provider communication to people living RMDs, 
there is also a need for health professionals and regu-
lators to acknowledge the use and capacity of apps to 
enhance patient–healthcare provider communication.42
Ptc 8: app design should consider accessibility of people with 
rMDs across ages and abilities
The accessibility of apps and their ease of use is an 
important point towards their implementation and 
sustainability. Age limit was discussed as these PtC do 
not specifically include the use of apps for children 
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and young people, since apps should be age and devel-
opmentally appropriate. The TF agreed on the impor-
tance of accessibility of apps, including the visual display 
and functionality (screen monitor, buttons, text boxes, 
literacy…).43 Indeed, app design should follow the prin-
ciple of universal design, and should be usable regardless 
of previous experience of mobile device use.25 44
Ptc 9: if a social network is an important component of an app, 
structures should be in place to ensure appropriate content 
moderation
Like other forms of social media, if apps allow public 
communication between users, they should include a 
moderation component (eg, someone to moderate live 
communication/interaction on communication plat-
forms, thus avoiding and/or removing inappropriate or 
harmful content).45 46 These structures have been defined 
in these PtC as a system in place for the app that can be a 
person or an automatic system that ensures appropriate 
content in the discussion.47 The TF emphasised that the 
app developer should be responsible for ensuring such 
structures exist and are enforced.
Ptc 10: the rheumatology community should consider the cost–
benefit balance of apps before endorsement and/or promotion
Financial affordability was discussed during the TF 
meeting. In our survey, the majority of people living with 
RMDs did not wish to pay for the apps.11 It was agreed by 
the TF that cost should be limited as much as possible, 
to remain affordable. Some discussion occurred on cost 
benefit. To date, only a few apps demonstrated their effi-
cacy in randomised controlled trials, and to our knowl-
edge, none focused specifically on the self-management 
of RMDs. It is expected that more studies will be published 
in the near future.48 49 The TF recommends that in that 
case, the development, promotion and purchase of apps 
should take cost–benefit balance into account.
Further steps
As part of this TF, areas of uncertainty pertaining to apps 
were discussed, defining directions for future research. 
These include a review and evaluation of existing app for 
self-management of RMDs against these EULAR PtC. The 
planification of a workshop with relevant stakeholders, 
including rheumatologists/health professionals, people 
living with RMDs and app developers, would also be 
helpful in order to define further collaborative projects. 
Finally, the development of an EULAR self-management 
app for people living with RMDs following these PtC 
could be of interest.
dIsCussIOn
These PtC for the development, evaluation and imple-
mentation of mHealth apps aiding self-management by 
people living with RMDs were informed by published 
evidence and mixed-method approaches involving direct 
patient feedback. The scope of these PtC is focused and 
limited to apps, as opposed to the more general concept 
of ehealth/digital health.50 The overall goal of this 
work was to enhance the process of app development, 
providing further elements for app standardisation, 
while ensuring safety and appropriateness for key stake-
holders. In an era of exponential growth in apps and in 
the absence of specific regulatory frameworks, the need 
for benchmarking the quality of mHealth apps to ensure 
patient safety is crucial. Three overarching principles and 
10 generic PtC for apps aimed at people living with RMDs 
have been developed which can be further used to: (1) 
measure the quality of existing mHealth apps and (2) 
inform the development of future mHealth apps.
During the meeting, the TF agreed on the principal 
importance of patient safety and data protection. eHealth 
data protection is a major concern and regulatory guide-
lines are in place to ensure that data is collected and 
stored in safe and compliant manners.36 37 However, the 
status of mHealth apps regarding this particular issue 
is still unclear. Indeed, mHealth apps need to have a 
‘medical purpose’ to fall under EU legislation, presenting 
some uncertainty as to whether the criterion of the 
intended medical use includes apps to promote self-man-
agement.26 Professional organisations could play a role 
in regulations around mHealth apps. These PtC include 
guidance on those important aspects, building on the 
Consolidated Standards of Reporting Trials (CONSORT-
EHEALTH) criteria for reporting studies involving 
web-based and mHealth interventions.51 This is a check-
list instrument that was constructed as an extension of 
the CONSORT statement. The CONSORT-EHEALTH 
reporting guidelines provide the basis for evaluating the 
validity and applicability of eHealth trials and should 
improve the reporting of findings.
The present work benefits from having incorporated a 
mixed-methods study to obtain direct patient feedback, 
owing to the lack of evidence on the topic.50 This ensured 
a more comprehensive picture was obtained, involving 
key stakeholders, namely patients. The research agenda as 
well as PtC takes this into account, and it is expected that 
these PtC will stimulate further research and publications 
on this topic. On the other hand, the mHealth field is 
rapidly moving with an increasing number of apps being 
accessible on the market based on user demand, making 
some of these PtC difficult to apply. Unfortunately, repre-
sentation from app developers and regulatory agencies 
were lacking as part of the TF. Further work arising from 
this will include the organisation of a workshop with app 
developers in order to gather their input on these PtC. 
Future implementation steps may include an analysis of 
the PtC impact on newly developed apps. Further ahead, 
a review of existing apps against these PtC should be 
conducted in order to assess their impact on the design 
and content. As part of the dissemination phase, we will 
also disseminate an electronic survey on agreement and 
feasibility among a larger panel of stakeholders, including 
rheumatologists/health professionals, people living with 
RMDs and app developers. Moreover, an update on these 
PtC will most likely to be required within the next 5 years, 
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accounting for the rapidly advancing area. It is suggested 
that such meetings should include app developers and/
or regulators where appropriate.
It is anticipated that EULAR, national societies, patient 
organisations, app developers and regulatory agen-
cies will use these PtC as a basis for the evaluation and 
endorsement of existing apps or the development of 
future apps aiding self-management by people living with 
RMDs.
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